MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202521015295 A) filed by Rungta International Skills University; Rungta College Of Engineering & Technology; and Rungta College Of Pharmaceutical Sciences And Research on February 22, 2025, for Therapeutic Use Of Inula Racemosa Extract For Pcos Management.
Inventors include Priya Komre; Trupti Tuse; Dr. Sanjay Kumar Gupta; Yamini Sahu; Sumit Sahu; Heena Rathod; Roshni Sharma; Bhavesh Sahu; and Anjali Singh.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: Therapeutic Use of Inula racemosa Extract for PCOS Management This invention describes a method tofor managing Polycystic Ovary Syndrome (PCOS) using an ethanolic extract derived from Inula racemosa roots. This system addresses the multifaceted nature of PCOS, including hormonal imbalances, oxidative stress, and ovarian dysfunction. The extract demonstrates anti-androgenic, antioxidant, and anti-inflammatory properties, effectively reducing testosterone levels, normalizing the estradiol-to-progesterone ratio, and improving ovarian morphology through follicular development and cystic follicle regression. Administered orally in a dose- dependent manner, the extract mitigates oxidative stress by neutralizing reactive oxygen species and reduces inflammatory cytokines to alleviate systemic and localized inflammation. The invention surpasses conventional PCOS therapies, such as clomiphene citrate, by offering superior efficacy with a natural, multi-targeted approach. This therapeutic system also incorporates precise storage, dispensing mechanisms, and quality control certifications to ensure safety, stability, and user compliance, making it a novel and effective solution for the comprehensive management of PCOS.
Disclaimer: Curated by HT Syndication.
